Bradykinin potentiator-5 | CAS#30505-63-6 | inflammatory mediator

MedKoo Cat#: 597860 | Name: Bradykinin potentiator-5

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bradykinin potentiator-5 is an inflammatory mediator. It is a peptide that causes blood vessels to dilate (enlarge), and therefore causes blood pressure to fall.

Chemical Structure

Bradykinin potentiator-5

CAS#30505-63-6

Theoretical Analysis

MedKoo Cat#: 597860

Name: Bradykinin potentiator-5

CAS#: 30505-63-6

Chemical Formula: C29H36N6O7

Exact Mass: 580.2645

Molecular Weight: 580.64

Elemental Analysis: C, 59.99; H, 6.25; N, 14.47; O, 19.29

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Bradykinin potentiator-5; BPP5a\; BPP-5a\; BPP 5a\;

IUPAC/Chemical Name

((S)-5-oxopyrrolidine-2-carbonyl)-L-prolyl-L-tryptophyl-L-alanyl-L-proline

InChi Key

UZDHHDZMTVGMLK-DEKCZCQOSA-N

InChi Code

InChI=1S/C29H36N6O7/c1-16(27(39)35-13-5-9-23(35)29(41)42)31-25(37)21(14-17-15-30-19-7-3-2-6-18(17)19)33-26(38)22-8-4-12-34(22)28(40)20-10-11-24(36)32-20/h2-3,6-7,15-16,20-23,30H,4-5,8-14H2,1H3,(H,31,37)(H,32,36)(H,33,38)(H,41,42)/t16-,20-,21-,22-,23-/m0/s1

SMILES Code

O=C(O)[C@H]1N(C([C@H](C)NC([C@H](CC2=CNC3=C2C=CC=C3)NC([C@H]4N(C([C@H](CC5)NC5=O)=O)CCC4)=O)=O)=O)CCC1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 580.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Balaguer JM, Yu C, Byrne JG, Ball SK, Petracek MR, Brown NJ, Pretorius M. Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial. Clin Pharmacol Ther. 2013 Apr;93(4):326-34. doi: 10.1038/clpt.2012.249. Epub 2012 Dec 24. PubMed PMID: 23361105; PubMed Central PMCID: PMC4031681. 2: Jiang Y, Xi X, Ge L, Yang N, Hou X, Ma J, Ma C, Wu Y, Guo X, Li R, Zhou M, Wang L, Chen T, Shaw C. Bradykinin-related peptides (BRPs) from skin secretions of three genera of phyllomedusine leaf frogs and their comparative pharmacological effects on mammalian smooth muscles. Peptides. 2014 Feb;52:122-33. doi: 10.1016/j.peptides.2013.12.013. Epub 2014 Jan 3. PubMed PMID: 24394432. 3: Shi D, Luo Y, Du Q, Wang L, Zhou M, Ma J, Li R, Chen T, Shaw C. A novel bradykinin-related dodecapeptide (RVALPPGFTPLR) from the skin secretion of the Fujian large-headed frog (Limnonectes fujianensis) exhibiting unusual structural and functional features. Toxins (Basel). 2014 Sep 29;6(10):2886-98. doi: 10.3390/toxins6102886. PubMed PMID: 25268979; PubMed Central PMCID: PMC4210874. 4: Uzawa A, Mori M, Taniguchi J, Kuwabara S. Modulation of the kallikrein/kinin system by the angiotensin-converting enzyme inhibitor alleviates experimental autoimmune encephalomyelitis. Clin Exp Immunol. 2014 Nov;178(2):245-52. doi: 10.1111/cei.12413. PubMed PMID: 24996009; PubMed Central PMCID: PMC4233374. 5: Maurer M, Bader M, Bas M, Bossi F, Cicardi M, Cugno M, Howarth P, Kaplan A, Kojda G, Leeb-Lundberg F, Lötvall J, Magerl M. New topics in bradykinin research. Allergy. 2011 Nov;66(11):1397-406. doi: 10.1111/j.1398-9995.2011.02686.x. Epub 2011 Aug 22. Review. PubMed PMID: 21859431. 6: Falsetta ML, Foster DC, Woeller CF, Pollock SJ, Bonham AD, Haidaris CG, Phipps RP. A Role for Bradykinin Signaling in Chronic Vulvar Pain. J Pain. 2016 Nov;17(11):1183-1197. doi: 10.1016/j.jpain.2016.07.007. Epub 2016 Aug 18. PubMed PMID: 27544818. 7: Sharif NA, Katoli P, Kelly CR, Li L, Xu S, Wang Y, Klekar L, Earnest D, Yacoub S, Hamilton G, Jacobson N, Shepard AR, Ellis D. Trabecular meshwork bradykinin receptors: mRNA levels, immunohistochemical visualization, signaling processes pharmacology, and linkage to IOP reduction. J Ocul Pharmacol Ther. 2014 Feb;30(1):21-34. doi: 10.1089/jop.2013.0105. Epub 2013 Nov 16. PubMed PMID: 24236827. 8: Barratt-Due A, Johansen HT, Sokolov A, Thorgersen EB, Hellerud BC, Reubsaet JL, Seip KF, Tønnessen TI, Lindstad JK, Pharo A, Castellheim A, Mollnes TE, Nielsen EW. The role of bradykinin and the effect of the bradykinin receptor antagonist icatibant in porcine sepsis. Shock. 2011 Nov;36(5):517-23. doi: 10.1097/SHK.0b013e3182336a34. PubMed PMID: 21921836. 9: Chen MM, O'Halloran EB, Ippolito JA, Choudhry MA, Kovacs EJ. Alcohol potentiates postburn remote organ damage through shifts in fluid compartments mediated by bradykinin. Shock. 2015 Jan;43(1):80-4. doi: 10.1097/SHK.0000000000000265. PubMed PMID: 25243425; PubMed Central PMCID: PMC4269565. 10: Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, Bork K, Lumry W, Aberer W, Bier H, Bas M, Greve J, Hoffmann TK, Farkas H, Reshef A, Ritchie B, Yang W, Grabbe J, Kivity S, Kreuz W, Levy RJ, Luger T, Obtulowicz K, Schmid-Grendelmeier P, Bull C, Sitkauskiene B, Smith WB, Toubi E, Werner S, Anné S, Björkander J, Bouillet L, Cillari E, Hurewitz D, Jacobson KW, Katelaris CH, Maurer M, Merk H, Bernstein JA, Feighery C, Floccard B, Gleich G, Hébert J, Kaatz M, Keith P, Kirkpatrick CH, Langton D, Martin L, Pichler C, Resnick D, Wombolt D, Fernández Romero DS, Zanichelli A, Arcoleo F, Knolle J, Kravec I, Dong L, Zimmermann J, Rosen K, Fan WT. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):532-41. doi: 10.1056/NEJMoa0906393. Erratum in: N Engl J Med. 2010 Oct 7;363(15):1486. PubMed PMID: 20818888; PubMed Central PMCID: PMC4662377. 11: Liu Z, Amouroux G, Zhang Z, Pan J, Hundal-Jabal N, Colpo N, Lau J, Perrin DM, Bénard F, Lin KS. (18)F-trifluoroborate derivatives of [des-arg(10)]kallidin for imaging bradykinin b1 receptor expression with positron emission tomography. Mol Pharm. 2015 Mar 2;12(3):974-82. doi: 10.1021/acs.molpharmaceut.5b00003. Epub 2015 Feb 9. PubMed PMID: 25629412. 12: Bras G, Bochenska O, Rapala-Kozik M, Guevara-Lora I, Faussner A, Kozik A. Extracellular aspartic protease SAP2 of Candida albicans yeast cleaves human kininogens and releases proinflammatory peptides, Met-Lys-bradykinin and des-Arg(9)-Met-Lys-bradykinin. Biol Chem. 2012 Aug;393(8):829-39. doi: 10.1515/hsz-2012-0157. PubMed PMID: 22944684. 13: Bujalska-Zadrożny M, de Cordé A, Cegielska-Perun K, Gąsińska E, Makulska-Nowak H. Dose-depending effect of intracerebroventricularly administered bradykinin on nociception in rats. Pharmacol Rep. 2013;65(4):1006-11. PubMed PMID: 24145095. 14: Gobeil F Jr, Sirois P, Regoli D. Preclinical pharmacology, metabolic stability, pharmacokinetics and toxicology of the peptidic kinin B1 receptor antagonist R-954. Peptides. 2014 Feb;52:82-9. doi: 10.1016/j.peptides.2013.12.009. Epub 2013 Dec 18. PubMed PMID: 24361511. 15: Chen X, Wang L, Wang H, Chen H, Zhou M, Chen T, Shaw C. A fish bradykinin (Arg0, Trp5, Leu8-bradykinin) from the defensive skin secretion of the European edible frog, Pelophylax kl. esculentus: structural characterization; molecular cloning of skin kininogen cDNA and pharmacological effects on mammalian smooth muscle. Peptides. 2011 Jan;32(1):26-30. doi: 10.1016/j.peptides.2010.09.023. Epub 2010 Oct 13. PubMed PMID: 20923691. 16: Hernández Fernandez de Rojas D, Ibañez E, Longhurst H, Maurer M, Fabien V, Aberer W, Bouillet L, Zanichelli A, Caballero T; IOS Study Group. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals. Int Arch Allergy Immunol. 2015;167(1):21-8. doi: 10.1159/000430864. Epub 2015 Jun 25. PubMed PMID: 26112099. 17: Martins AH, Alves JM, Perez D, Carrasco M, Torres-Rivera W, Eterović VA, Ferchmin PA, Ulrich H. Kinin-B2 receptor mediated neuroprotection after NMDA excitotoxicity is reversed in the presence of kinin-B1 receptor agonists. PLoS One. 2012;7(2):e30755. doi: 10.1371/journal.pone.0030755. Epub 2012 Feb 10. PubMed PMID: 22348022; PubMed Central PMCID: PMC3277507. 18: Manders K, van Deuren M, Hoedemaekers C, Simon A. Bradykinin-receptor antagonist icatibant: possible treatment for ACE inhibitor-related angio-oedema. Neth J Med. 2012 Oct;70(8):386-7. PubMed PMID: 23065991. 19: Geiger R, Hell R, Fritz H. Determination of bradykinin, kallidin and Met-Lys-bradykinin by high performance liquid chromatography. Hoppe Seylers Z Physiol Chem. 1982 May;363(5):527-30. PubMed PMID: 7095757. 20: Javaud N, Lapostolle F, Sapir D, Dubrel M, Adnet F, Fain O. The early treatment of bradykinin angioedema, a challenge for emergency medicine. Eur J Emerg Med. 2013 Aug;20(4):291-2. doi: 10.1097/MEJ.0b013e32835bb4a9. PubMed PMID: 23154214.